RGT (ASX) Mxc-social media

Originally posted by PeterKing ↑

Now that Aroura has been granted a plot in Malta, it leaves Canopy Growth somewhat lagging in the European MC stakes. The 2^nd largest Cap MC company (Aroura) has one up on the global MC behemoth, Canopy.

View attachment 1211468
Canopy have three companies in Europe namely Alcaliber (Spain), Spectrum Cannabis (Denmark) and Spektrum Cannabis (Germany)

Alcaliber (Spain)
I am not sure what value this company is to Canopy other than its ties to the Opiate based European pharmaceutical network. Perhaps they plan at a later stage to utilise these connections to infiltrate BIG Pharma with assorted MC products, if / when they get them in production.

From what I can gather, Alcaliber neither grows Cannabis nor refines to produce CBD. It appears to be a 100% grower and producer of opiates.

“We are proud to have one of the most modern plants in the world for the production of opiates, in accordance with the most demanding GMP quality standards.
Poppy straw rich in alkaloids is harvested and transported to Alcaliber ‘s Industrial Plant for extraction, purification and preparation of narcotic raw materials and API’s.”

Spectrum Cannabis (Denmark)
You could be mistaken for thinking this is simply a ‘front’ for future MC adventures fostered by Canopy. The small ‘info’ website is all in Danish with no English translated option. The guts of it translates to ………….

"January 1, 2018 marked the start of the Danish trial scheme for treatment of patients with medical cannabis. Thus, the framework is created to help a variety of patient groups as well as to generate new knowledge in order to add additional evidence of the impact of medical cannabis products.

It is important for us to be part of the cooperation between patients, doctors, researchers and producers in the trial scheme."
They appear to have no growing or processing here whatsoever.

Spektrum Cannabis (Germany)
Again, the website is not in English but one section translates as –

“Spektrum Cannabis is GMP certified and operates under strict guidelines. The products distributed are based on a long tradition of using cannabis as a medicinal herb, as well as the latest findings in cannabinoid research. Since 2016, Spektrum Cannabis GmbH has been supplying cannabis flowers of the highest quality to German pharmacies.”

Based on the above, it appears Canopy have no growing facilities in Europe nor do they have a processing plant. The only GMP facility appears to be at Alcaliber where it is 100% dedicated to producing ‘opiates’ – the basis for pain killing drugs produced by Big Pharma that are directly responsible for killing 175 people in the USA every single day!

For some sobering confirmation click here.

With opiates killing over 64,000 people every year in the US alone, it begs the question….

“What is a Cannabis based mega company like Canopy doing siding with a company that produces opiates, which are seen to be the pharma opposition to Medical Cannabis?”

If anything, Canopy seems to be in desperate need a bonafide European MC producer (like MXC) that ticks all the boxes and would greatly enhance the operability and profitability in Europe.

If Canopy did make an offer for MXC, I’d be jumping for joy!

Expand

Very interesting reading....thank you @PeterKing.

If & when MXC have a product for chronic pain, be great to discuss that here. Opioids have their place in severe acute pain & severe chronic pain (ie terminal cancer) but in absolute agreeance regarding overuse, addiction & the risks of overdose.

It would be great for patients & their Drs to have more options to treat pain, because there is a greater understanding of addiction risks & also we’ve seen a big crackdown on codeine availability recently in Australia.

I believe Big Pharma will be looking with interest at MC once the $ signs appear & some stigma disappears in the medical & pharmaceutical fields. So what are Canopy up to?

No.	Vol.	Price($)
1	50168	25.0¢

No.

Vol.

Price($)

50168

25.0¢

Price($)	Vol.	No.
27.0¢	730	2

Price($)

Vol.

No.

27.0¢

730

No.	Vol.	Price($)
1	50168	0.250
1	13141	0.240
1	2200	0.230
1	3927	0.220
1	5000	0.190

No.

Vol.

Price($)

50168

0.250

13141

0.240

2200

0.230

3927

0.220

5000

0.190

Price($)	Vol.	No.
0.270	730	2
0.280	1219	1
0.290	1753	1
0.300	2129	2
0.350	294	1

Price($)

Vol.

No.

0.270

730

0.280

1219

0.290

1753

0.300

2129

0.350

294

(20min delay)
Last 26.0¢		Change 0.030(13.0%)		Mkt cap ! $12.58M

Open	High	Low	Value	Volume
19.0¢	26.0¢	19.0¢	$15.18K	61.66K

Mxc-social media, page-134

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Fourfold skarn increase points the way to viable garnet project, says Pure

Good habits matters when it comes to finances

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Mxc-social media, page-134

Top Stories

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Earnings wrap Monday Week 34: A2 Milk, Bluescope, Suncorp's climate woes & more

Gold intercept of 8.6 g/t continues the positive storyline for Santana at NZ's RAS deposit

Fourfold skarn increase points the way to viable garnet project, says Pure

Good habits matters when it comes to finances

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News